<DOC>
	<DOC>NCT02143713</DOC>
	<brief_summary>A randomized study evaluating the continued safety and efficacy of elagolix in the management of moderate to severe endometriosis associated pain in adult pre-menopausal female subjects who completed 6 months treatment in Study M12-671.</brief_summary>
	<brief_title>Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-associated Pain</brief_title>
	<detailed_description />
	<mesh_term>Endometriosis</mesh_term>
	<criteria>Subject has completed the 6Month Treatment Period in pivotal study M12671. Agrees to use required birth control methods during the study through Month 6 of the Posttreatment Followup period Clinically significant gynecological condition Bone mineral density (BMD) loss greater than or equal to 8 percent in the spine, femoral neck or total hip Plans to become pregnant in the next 18 months</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Dyspareunia</keyword>
	<keyword>Endometriosis-associated pain</keyword>
	<keyword>Dysmenorrhea (DYS)</keyword>
	<keyword>Elagolix</keyword>
	<keyword>Gonadotropin-releasing Hormone Antagonist</keyword>
	<keyword>Non-menstrual Pelvic Pain (NMPP)</keyword>
</DOC>